Answers are grounded in this paper and cite their sources.
γ-Radiation-mediated catalytic decaging (γ-RCD) activates functional molecules in tumor-bearing mice, highlighting a new approach for precision medicine.
Precise spatiotemporal control over chemical reactivity in living systems remains a formidable challenge, especially within deep tissues where light-based methods suffer from limited penetration. Here, we present a γ-radiation-mediated catalytic decaging (γ-RCD) strategy that harnesses hydrated electrons generated during low-dose γ-radiation to activate palladium catalysts, thereby initiating a catalytic cycle for the efficient release of functional molecules. Unlike conventional radiation-triggered decaging, which relies on primary radiolytic species and suffers from inherently low yields, γ-RCD achieves catalytic amplification, significantly enhancing radiochemical efficiency with G-values up to 25.8-surpassing existing radiation chemistries by at least 20-fold. We demonstrate the versatility of γ-RCD in remotely activating fluorophores, prodrugs as well as proteins with minimal radiation input, both in vitro and in vivo. Notably, this strategy enables selective activation of caged bioactive compounds in living cells and tumor-bearing mice, leading to potent antitumor effects. Moreover, the method achieves deep-tissue protein activation, establishing a generalizable platform for radiation-directed gain-of-function studies on biomolecules in living systems. By integrating catalytic amplification with clinically relevant γ-radiation, γ-RCD opens a new avenue for precision medicine, functional biomaterials, and radiation-responsive therapeutics.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: